European listed biotech landscape: 2020 review and outlook for 2021

Table of Content 1. Intro on COVID-19 2. How the European listed biotech companies try to help for vaccines and therapies against COVID-19 3. 2020 Highlights (financing, Genmab, Morphosys, approvals, “Billion Euro Biotech Club”, valuations) 4. 2020 Lowlights (Galapagos, Genfit, DBV, IPOs, AIM) 5. 2020 Deals and M&As 6. 2020 Stock and Index Performances 7.[…]

We Are Now Open!

Dear all, this is my great pleasure to announce the launch of biotechradar.eu today. This is a subscription service for pro-investors and profressionals in Life Sciences, providing data and intel on the European landscape of public biotech companies. Pipeline data and financials are obviously the backbones of the service, but there’s indeed more. The underlying[…]